Companion Animal Arthritis Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

PUBLISHED: August 14, 2024

PAGES: 196 Pages

DELIVERY TIME: 2-3 business days

ADD TO COMPARE

SELECT AN OPTION

Description

The Global Companion Animal Arthritis Market, valued at approximately USD 3.4 billion in 2023, is set to grow at a CAGR of 7.2% from 2024 to 2032. Increasing pet ownership is a primary driver for the market's growth. This rise has spurred demand for healthcare products for companion animals, including medications and supplements. The National Pet Owners Survey by the American Pet Products Association reveals that around 86.9 million American families, or 66%, own pets, spanning from birds and cats to dogs and ferrets. Moreover, the global uptick in pet adoption, coupled with technological strides in veterinary medicine-like advanced diagnostic tools and more potent treatment options-fuels market growth. These advancements boost treatment efficacy and expand the range of treatable conditions.

Veterinary clinics are increasingly utilizing advanced imaging techniques, such as MRI (magnetic resonance imaging) and CT (computed tomography) scans, to diagnose joint issues in pets. These tools offer veterinarians a clearer view of joint structures, allowing for more precise treatment plans. Furthermore, the market is driven by innovative therapeutic technologies and devices, including laser treatments, tailored rehabilitation programs, and activity monitors.

The overall companion animal arthritis industry is segmented based on treatment type, disease type, animal type, end-use, and region.

The market is segmented by treatment type into medication, food supplements, surgery, and other treatments. In 2023, the medication segment is projected to account for USD 1.5 billion. To alleviate arthritis symptoms in companion animals, veterinarians commonly prescribe pharmaceutical drugs like NSAIDs, corticosteroids, and disease-modifying osteoarthritis drugs (DMOADs), emphasizing pain relief and inflammation reduction. Advancements in veterinary medicine-ranging from enhanced diagnostics to robust medications and holistic treatment protocols-have improved the effectiveness and accessibility of arthritis treatments.

Segmented by disease type, the companion animal arthritis market includes osteoarthritis, rheumatoid arthritis, and other forms. In 2023, osteoarthritis led the market with a commanding 64.3% share. Osteoarthritis, prevalent in pets, impacts nearly 20% of older dogs and cats, leading to joint cartilage degeneration and subsequent bone changes. The rising consumer inclination towards natural and holistic remedies-like nutraceuticals such as glucosamine, chondroitin, and omega-3 fatty acids-signals an uptick in demand for products addressing osteoarthritis in dogs, thus propelling market growth.

North America held a dominant 45.6% share of the global companion animal arthritis market in 2023, with forecasts suggesting continued robust growth. Key drivers for North America's market expansion include surging pet ownership, increased awareness of animal health, and advancements in veterinary care. As the pet care landscape evolves, North American stakeholders-especially those innovating and addressing unique market needs-are poised for significant gains.

Product Code: 10785

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
  - 1.5.1.1 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising trend of pet adoption
  - 3.2.1.2 Technological innovation in treatments of arthritis for companion animals
  - 3.2.1.3 Increasing prevalence of arthritis in aging pets
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High costs associated with advanced diagnostics, medications, and specialized treatments
  - 3.2.2.2 Limited research and development
3.3 Growth potential analysis
3.4 Technological landscape
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Medication
- 5.2.1 NSAIDs
- 5.2.2 Monoclonal antibodies
- 5.2.3 Other medications
5.3 Food supplement
5.4 Surgery
5.5 Other treatment types

Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Osteoarthritis
6.3 Rheumatoid arthritis
6.4 Other arthritis types

Chapter 7 Market Estimates and Forecast, By Animal Type, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Dogs
7.3 Cats
7.4 Other animals

Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Veterinary hospitals
8.3 Veterinary clinics
8.4 Veterinary rehabilitation centers
8.5 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 Rest of Middle East and Africa